This pack has been prepared ahead of the debate to be held in Westminster Hall on Wednesday 1 November 2017 from 9.30-11am. The debate will be opened by Gareth Johnson MP.Jump to full report >>
Unlike conventional cigarettes, e-cigarettes do not contain tobacco, do not involve burning and thus do not produce carbon monoxide, tar or smoke. They work by heating a solution of water, flavouring, propylene glycol, and, typically, nicotine to create a vapour that the user inhales. Using an e-cigarette is often described as ‘vaping’ rather than smoking. It was estimated in 2017 that 2.9 million people aged 18 and over in Great Britain were using e-cigarettes, up from 700,000 in 2012. Survey data indicates that consumers are increasingly turning to e-cigarettes as a means to cut back on smoking tobacco, or to quit tobacco completely.
Debates on the benefits and risks of e-cigarettes, particularly regarding their safety and health implications, are ongoing and will continue as more evidence gradually becomes available. A review of the evidence to date, commissioned by Public Health England, reported in 2015 that “best estimates show that e-cigarettes are 95% less harmful to your health than normal cigarettes” and that there was no current evidence to show that they were renormalising smoking, or increasing the uptake of tobacco cigarettes.
Different approaches to regulating e-cigarettes have been adopted internationally. Prior to the introduction of the Tobacco Products Directive (TPD), the UK initially regulated e-cigarettes as consumer products that were subject to existing product safety regulations. Some countries went further and banned the sale, distribution and importation of e-cigarettes, while others have no regulations in place. An alternative approach, considered by the UK Government, was to regulate all nicotine-containing e-cigarettes as medicines. While the UK Medicines and Healthcare products Regulatory Agency set out plans in 2013 to implement this approach, they were superseded by the introduction of the TPD.
The European Union Tobacco Products Directive entered into force on 19 May 2014, with the UK Tobacco and Related Products Regulations 2016 implementing the TPD in full across the UK. According to the European Commission, the TPD’s aim is to “improve the functioning of the internal market for tobacco and related products while ensuring a high level of health protection for European citizens”. Article 20 of the TPD introduces new regulatory controls for nicotine-containing e-cigarettes and refill containers, though it does not cover nicotine-containing products that are authorised as medicines. These controls aim to ensure:
The TPD does not seek to harmonise rules on:
These elements can all be regulated at a domestic level. England, Northern Ireland, Scotland and Wales have each introduced age restrictions on e-cigarettes that prohibit their sale to, and their purchase on behalf of, under 18s. In 2015/16 the Welsh Government attempted to go further and introduce controls on the use of e-cigarettes in public places, though the Bill was subsequently rejected by the Welsh Assembly. The Scottish Government has made provision, through the Health (Tobacco, Nicotine etc. and Care) (Scotland) Act 2016, to restrict the advertising of vapour products through secondary legislation, though this is not yet in place.
On 25 October 2017, the House of Commons Science and Technology Select Committee launched an Inquiry to look at the science behind e-cigarettes and the impact on health, the regulation of the products and financial implications.
The terms of reference of the inquiry have been published and the Committee is accepting written evidence until 8 December 2017.
Commons Debate packs CDP-2017-0203
Authors: Nikki Sutherland; Sarah Barber